跳至主要内容
临床试验/NCT02979730
NCT02979730已完成不适用

Proposal to Evaluate the Impact of Point of Care Liat Influenza A/B Testing in the Emergency Department at Boston Medical Center

Boston Medical Center1 个研究点 分布在 1 个国家目标入组 233 人开始时间: 2017年2月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
233
试验地点
1
主要终点
Time to Disposition

研究概览

简要总结

The purpose of the study is to compare Emergency Department patients who undergo influenza testing using an FDA-approved point-of-care device (Cobas Liat Influenza A/B assay) located in the ED, to patients whose samples are sent to the BMC central laboratory. Patients who agree to participate will have their samples randomly assigned to be tested on either at the core lab, or on the POC device. The current turnaround time for samples sent to the laboratory is approximately two hours; investigators expect that the point of care device can reduce this time. Investigators will determine if the time to disposition and the administration of antibiotics is different in the group undergoing POC influenza testing compared to those undergoing laboratory-based influenza testing

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adult patients 21 years of age or older
  • •Presenting to the BMC main ED or Urgent Care area with influenza-like illness
  • •Physician ordered an influenza A/B diagnostic test

排除标准

  • •Previously enrolled in the study
  • •Any Influenza test result already available at the time approached by the ED RA
  • •Physician ordered comprehensive multiplex PCR respiratory pathogen assay instead of an initial influenza A/B-only test.
  • •Unable to give informed consent

研究组 & 干预措施

Core Lab Testing Arm

Active Comparator

For patients with clinical concern for influenza, the usual workflow in the BMC ED is that physicians order the collection of a nasopharyngeal swab (NPS) for influenza A/B testing to be performed in the core microbiology laboratory using one of two assays. The two influenza A/B-only assays available in the core lab are a) an instrumented fluorescent immunoassay rapid antigen test, the Sofia influenza A+B FIA (Quidel Corporation) and b) an automated real-time PCR test, the Xpert Flu (Cepheid, Inc.). Which test is ordered is at the discretion of the physician. Both the Sofia and Xpert assays provide a result callout to distinguish influenza type A from type B.

干预措施: Core Lab Test (Other)

ED Point of Care Testing Arm

Experimental

Prior to the study the Cobas Liat Influenza A/B assay will be verified for patient care at BMC. The instrument and test kits will be available in the ED for use with study subjects randomized to this study arm. The Cobas Liat assay provides a result callout to distinguish influenza type A from type B.

干预措施: ED Point of Care Test (Other)

结局指标

主要结局

Time to Disposition

时间窗: By the End of the ED visit (an average time of 4 hours)

The time elapsed from when a patient was placed in the ED treatment room until the disposition (either admit, observe, or discharge) was ordered in the medical record

次要结局

  • Delivery of prescription or administration of antibiotics(by the end of ED visit (an average time of 4 hours))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Elissa Schechter-Perkins

Principal Investigator

Boston Medical Center

研究点 (1)

Loading locations...

相似试验